Download App
Help CenterSubscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Camlin Fine Sciences Ltd (CAMLINFINE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532834 NSE: CAMLINFINE Chemicals | Small Cap | Camlin Fine Sciences Share Price

₹96.40 -0.95 (-0.98%)

As on 28-Sep'26 10:17

Camlin Fine Sciences Ltd (CAMLINFINE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532834 NSE: CAMLINFINE Chemicals | Small Cap | Camlin Fine Sciences Share Price

₹96.40 -0.95 (-0.98%)

As on 28-Sep'26 10:17

Key Metrics
Valuation Multiples
Market Cap
₹1,870 Cr.
Current Price
₹96.4
52-Week Low / High
₹96 / 218
TTM EPS
₹0.3
TTM Sales
₹1,862 Cr.
Book Value per Share
₹51.6
P/E Ratio
317.93
Industry PE
48
Price to Book (P/B)
1.89
Lower than its 5-year historical median
Price to Sales (P/S)
1.00
Lower than its 5-year historical median
EV/EBITDA
20.10
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-3.30%
Underperforms industry median
Return on Capital Employed (ROCE)
3.16%
Underperforms industry median
Return on Assets (ROA)
-1.50%
Operating Profit Margin
6.9%
Net Profit Margin
-1.83%
Gross Profit Margin
3.6%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-5.48%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-48.4%
Net Profit Growth (1 Year)
-
-148.44%
Asset Quality
Promoter Holding
48.03%
Pledged shares (%) of Promoter's holding (%)
16.21%
Reserves
₹973 Cr.
Equity
₹19.2 Cr.
Face Value
₹1
All Time Low / High
₹1.90 / 334.70

Camlin Fine Sciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Not Good
Check detailed performance

Valuation

Somewhat Undervalued

Check Valuation charts

Price Trend

Weak
Check Price chart
Q.1 Is Camlin Fine Sciences Ltd a good quality company?
Camlin Fine Sciences Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Camlin Fine Sciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Camlin Fine Sciences Ltd vs industry peers?
Camlin Fine Sciences Ltd revenue CAGR is 7.74%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Camlin Fine Sciences Ltd?
Promoters hold 48.03% of the Camlin Fine Sciences Ltd, with 16.21% of their stake pledged, indicating high pledge risk.
Q.1 Stock return of Camlin Fine Sciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 1.2% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Camlin Fine Sciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ7.4%1.7%6.2%10.6%6.9%7.7%11.3%0.2%-3.9%1.6%-
Value Creation
Index ⓘ		-0.5-0.9-0.6-0.2-0.5-0.5-0.2-1.0-1.3-0.9-

Growth Parameters ⓘ
Sales ⓘ325403548580600686789773886838869
Sales YoY Gr.-24.1%36.1%5.8%3.5%14.2%15.2%-2.1%14.6%-5.5%-
Adj EPS ⓘ0.2-1.30.71.61.11.21.9-3.1-0.7-2-1.8
YoY Gr.--816.7%NA129.6%-32.5%10%59.5%-261.7%NANA-
BVPS (₹) ⓘ16.424.926.230.331.736.13940.945.147.546.9
Adj Net
Profit ⓘ		1.9-16.18.820.214.419.431.1-53.6-13.9-37.5-35
Cash Flow from Ops. ⓘ-30.1-5.2-44.673.92646.818.582.118.144-
Debt/CF from Ops. ⓘ-8.1-41.7-74.514.39.632.6622.710.7-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ11.1%6.9%2%-5.5%
Adj EPS ⓘ-230.3%-212.1%-200.3%NA
BVPSⓘ12.6%8.5%6.8%5.3%
Share Price 1.2% -11.9% -15.5% -54.3%

Key Financial Parameters ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ		1.3-6.32.65.63.43.75-7.9-1.8-4.2-3.8
Op. Profit
Mgn % ⓘ		8.51.1610.412.411.616.84.38.96.85.8
Net Profit
Mgn % ⓘ		0.6-41.63.52.42.83.9-6.9-1.6-4.5-4
Debt to
Equity ⓘ		1.40.710.90.90.810.70.50.5-
Working Cap
Days ⓘ		322338305315338344366415348366195
Cash Conv.
Cycle ⓘ		18118015216216816519323316316069

Valuation of Camlin Fine Sciences - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *12.4312.4312.4312.4310.840.0010.8410.8416.5816.21
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales5347218921,0491,1871,4121,6821,4541,6291,723
Operating Expenses ⓘ + 5037068199141,0001,2581,4691,3131,4021,606
Manufacturing Costs7796122127167199312201206217
Material Costs261422475534583759813770824922
Employee Cost 617388100120145163153185244
Other Costs ⓘ 104115135153129154182190187223
Operating Profit ⓘ 311573135187154212141226117
Operating Profit Margin (%) 5.7%2.0%8.2%12.9%15.7%10.9%12.6%9.7%13.9%6.8%
Other Income ⓘ + 161314311376441529
Exceptional Items ⓘ 000000-100-10-25
Interest ⓘ 313241484841667010783
Depreciation ⓘ 22272933445663566171
Profit Before Tax ⓘ -6-31175810594805965-32
Tax ⓘ -2-714284034416-1-0
Profit After Tax -4-243306560405365-32
PAT Margin (%) -0.8%-3.3%0.3%2.8%5.5%4.3%2.4%3.6%4.0%-1.8%
Adjusted EPS (₹)-1.1-2.40.12.43.93.83.2-5.4-7.41.4
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 2113493484035927368058518881,025
Share Capital ⓘ 10.3712.1212.1312.1312.7515.7015.7116.7518.7919.21
Reserves ⓘ 2013373363915797207898348691,006
Debt +321357438490490569641566510526
Long Term Debt51110194212273388408333268303
Short Term Debt270247244278217181233233241223
Minority Interest1862595770175-8-27-40
Trade Payables78178165174158234288325407505
Others Liabilities ⓘ 20313570138208291177182221
Total Liabilities ⓘ 6489771,0461,1931,4491,7642,0301,9111,9592,237

Fixed Assets

Net Fixed Assets ⓘ +199276270304581601858832702887
Gross Block2123403574287588301,1241,1781,2921,365
Accumulated Depreciation136487124177229267346591478
CWIP ⓘ 814591792421543461033
Investments ⓘ 1911511777886130
Inventories198239285298320371568513527504
Trade Receivables145205209253271300305285328373
Cash Equivalents 3148103651381429994154153
Others Assets ⓘ 497910788107128150134178256
Total Assets ⓘ 6489771,0461,1931,4491,7642,0301,9111,9592,237
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + -9-15-986117145511392382
PBT ⓘ -6-3117581059480-99-15823
Adjustment ⓘ 474170871147813025430146
Changes in Working Capital ⓘ -39-15-80-41-664-13932-8237
Tax Paid ⓘ -10-10-16-18-36-30-20-48-38-24
Cash Flow From Investing Activity ⓘ + -83-149-2-90-133-249-125-66-75-53
Capex -31-19-69-134-84-214-143-60-42-58
Net Investments -11-946341-502828-8-352
Others ⓘ -42-36431-64-9123
Cash Flow From Financing Activity ⓘ + 911822633913660-8676-25
Net Proceeds from Shares ⓘ 581480001112231
Net Proceeds from Borrowing ⓘ 2665-1617231068125-5669
Interest Paid ⓘ -26-29-57-39-48-25-52-73-70-61
Dividend Paid ⓘ -50-6-3-5-1-14000
Others ⓘ 38-210528695644-39-21-34
Net Cash Flow ⓘ -11815-12332-14-13244
PARTICULARSMar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)-2.29-8.570.867.9414.6110.555.716.857.69-3.3
ROCE (%)5.460.177.3212.0215.2511.3710.388.5311.443.16
Asset Turnover Ratio0.980.890.880.940.90.880.890.740.840.82
PAT to CFO Conversion(x)N/AN/A-32.871.82.421.282.620.35N/A
Working Capital Days
Receivable Days73.5088.4084.8080.4080.5073.7065.607468.7074.30
Inventory Days123.90110.30107.30101.509589.30101.90135.70116.50109.10
Payable Days121.70110.70131.60115.70103.9094.20117.20145.30162.10180.40

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Camlin Fine Sciences Ltd FAQs

The current trading price of Camlin Fine Sciences on 28-Sep-2026 10:17 is ₹96.40.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 27-Sep-2026 the market cap of Camlin Fine Sciences stood at ₹1,870.1 Cr

The latest P/E ratio of Camlin Fine Sciences as of 27-Sep-2026 is 0.00.

The latest P/B ratio of Camlin Fine Sciences as of 27-Sep-2026 is 2.08.

The 52-week high of Camlin Fine Sciences is ₹218.0 and the 52-week low is ₹95.95.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Camlin Fine Sciences is ₹869 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Camlin Fine Sciences Ltd is a below average quality company.

The key valuation ratios of Camlin Fine Sciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Camlin Fine Sciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Camlin Fine Sciences Ltd

Camlin, the corporate group, was established in 1931 and is a pioneer in art and stationery material in India. Camlin diversified into Pharmaceuticals and Fine Chemicals two decades ago. The Fine Chemical Division of Camlin got de-merged into a separate company named as Camlin Fine Chemicals on 22nd December 2006. The entire management team and employees of Camlin Fine Chemicals Division are now a part of the independent legal entity formed under the Indian Companies Act 1956. In 2011
Company changed its name from Camlin Fine Chemicals Ltd. to Camlin Fine Sciences Ltd. 

Camlin Fine Chemicals is the world's second largest manufacturer and marketer of food grade antioxidants TBHQ and BHA. Its mission is to be the largest food antioxidant and ingredient manufacturer worldwide. Their facilities are HACCP and ISO 9001 : 2000 certified.

Product Range:

a) Food Ingredients –

Antox TBHQ (HACCP Certified) FCC V / FAO / WHO (Tertiary Butyl Hydroquinone)

Antox BHA (HACCP Certified) FCC V / FAO / WHO / EEC ( Butyl Hydroxy Anisole)

b) Sweetener -

Sucralose FCC V

c) Active Pharmaceutical Ingredients -

  • Miconazole Nitrate B.P. / USP
  • Clotrimazole B.P. / USP
  • Amlodipine Besilate E.P
  • Amlodipine Salts
  • Advance intermediate of Amlodipine
  • Intermediate of Miconazole Nitrate

d) Super Absorbent Polymer

Subsidiary Details:

  • Chemolutions Chemicals: Specialty Chemical Intermediates
  • Sangam Laboratories: Nutraceuticals
  • Fine Renewable Energy.
  • Fine LifeStyle Brands: Luxury Fashion Brands

On 6th June 2008 - The company entered into a joint venture, on 51:49 basis, with US based Viachem LLC, to set up a joint venture company under the name Dulcette Technologies for marketing Sucralose, Aspartame, and Acesulfame-K, and their belnds in USA, Canada, and Maxico.

On 7th July 2008 - The Board of Directors of the company at its meeting held on 29th July 2008, approved the proposal for setting up a joint venture company with Pagoda Advisors and their associates.

As per the deal, Camlin Fine Chemicals will get 51% of the equity of the proposed new company and the rest 49% will be owned by Pagoda Advisors and their associates.The proposed new company will focus on the retail of luxury/premium brands in India by setting up stores in all stores in all major metros and cities in India by itself and through franchisees.

On 25th February 2008:  Camlin Fine Chemicals acquired 60% equity stake in Sangam Laboratories, a Small Scale Unit manufacturing Nutraceuticals and Drug Intermediates at Tarapur.

On 12th February 2008 - The company inked a joint venture deal with US based Advanced Aerospace Technologies to manufacture and market speciality fine chemicals primarily to cater to European and U.S markets.

You have 47 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now